Skip to content

Effect of tegileridine postoperative analgesia on gastrointestinal function recovery after laparoscopic hysterectomy: a single-center, double-blind, randomized controlled clinical trial

Effect of tegileridine postoperative analgesia on gastrointestinal function recovery after laparoscopic hysterectomy: a single-center, double-blind, randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109567
Enrollment
Unknown
Registered
2025-09-22
Start date
2025-09-23
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing laparoscopic hysterectomy

Interventions

Tegileridine postoperative analgesia group (Group E):Tegileridine was used for postoperative intravenous controlled analgesia
Sufentanil postoperative analgesia group (Group S):Sufentanil was used for postoperative intravenous controlled analgesia

Sponsors

Chengdu Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Female, aged 18-65 years; 2. Body mass index (BMI) 18.0-30.0 kg/m^2; 3.ASA grade ?-?; 4. Patients undergoing elective laparoscopic hysterectomy and requiring postoperative patient-controlled intravenous analgesia; 5. Understand the purpose and procedures of the trial, voluntarily participate in the trial, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Use opioid drugs or tramadol for more than 7 days before the operation; 2. Chronic pain, constipation, other intestinal dysfunction before surgery or after radiotherapy and chemotherapy; 3. Those who are allergic to opioid drugs or anesthetic and analgesic drugs specified in the protocol; 4.1 History of drug and alcohol abuse within the year; 5. Liver dysfunction; 6. Severe respiratory depression, such as oxygen saturation below 90%; 7. Known or suspected gastrointestinal obstruction, including paralytic ileus; 8. History of surgery involving the intestines, bladder or gastrointestinal tract; 9. The researchers believe that the subjects cannot tolerate it, cannot cooperate to complete the trial, or have other situations where they are not suitable to participate.

Design outcomes

Primary

MeasureTime frame
The time of first postoperative exhaust;

Secondary

MeasureTime frame
The time of regular meal;The time of tolerate solid food;The time of first defecation;Incidence of postoperative intestinal obstruction;Postoperative blood potassium level;Resting and exercise pain scores (NRS) at 0.5, 2, 6, 12, 24, 48 hours after surgery;Complications of analgesia ;Ramsay score;Postoperative analgesic drug consumption in12, 24, 36, 48 hours;Times of PCA;Times of remedial analgesia;RCSQ score on the day of surgery and the day after surgery;Postoperative recovery quality scores 24 hours, 48 hours, and one week after surgery (QOR-15);

Countries

China

Contacts

Public ContactYu Huang

Chengdu Second People's Hospital

982646506@qq.com+86 183 0831 6694

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026